Bruising and Bleeding

 

Bruising and bleeding more easily than normal may be a side effect of your cancer treatment. The most common reason for cancer patients to experience excessive bruising or bleeding is a low platelet count, a condition also referred to as thrombocytopenia. Platelets are necessary for blood clotting. If thrombocytopenia is determined to be the cause of your bruising and bleeding, you may be given a platelet transfusion or prescribed a blood cell growth factor, which stimulates your bone marrow to produce more platelets and helps prevent low platelet counts after chemotherapy.

How are bruising and bleeding similar?

Bleeding is loss of blood outside the body or into a body cavity. A bruise, also called a purpura (if flat) and a hematoma (if large), is bleeding into the skin from damaged blood vessels, causing a black and blue appearance.

What causes bruising and bleeding?

Bruising and bleeding are usually caused by some kind of trauma or injury. However, certain underlying conditions may cause you to bruise or bleed more easily than normal. The most common reason for this in cancer patients is a low platelet count, a condition also referred to as thrombocytopenia.

Platelets, also called thrombocytes, are fragments of blood cells which are found in the circulating blood and are critical for stopping bleeding. Platelets plug the small holes that form in blood vessels daily and work with other blood factors to form a blood clot, which stops bleeding in larger blood vessel injuries.

There are, however, many other possible causes for bruising and bleeding, including several other bleeding disorders that are caused by a lack of various blood factors that are essential for clotting.

What are the symptoms of a low platelet count?

Here are some clues that may indicate that you have a low platelet count or another bleeding disorder.

  • You bleed excessively and even a small cut bleeds for a long time.
  • You may develop small red dots on the surface of your skin, especially on your legs, which are called petechiae.
  • You have excessive bruising, including many purplish spots under the skin even when you haven’t had an injury.
  • You may have frequent nose bleeds or bleeding from your gums and mouth.

Notify your doctor immediately if you have any of these symptoms.

What is the treatment for bruising and bleeding?

If the bruising and bleeding you are experiencing is determined to be a consequence of a low platelet count, your doctor may prescribe a blood cell growth factor. Blood cell growth factors are substances produced by your body to stimulate the bone marrow to produce more platelets. They are usually prescribed to help prevent low platelets. If you have a severely low platelet count, you may require treatment with platelet transfusions and, occasionally, admission to the hospital until the platelets return to sufficient levels in the blood to prevent bleeding.

Neumega® (oprelvekin) - This is the blood cell growth factor approved by the U. S. Food and Drug Administration for the prevention of a low platelet count. Clinical studies have shown that oprelvekin prevents thrombocytopenia and decreases the need for platelet transfusions in some patients at high risk for developing a low platelet count.

Platelet transfusion - A platelet transfusion is the addition of platelets into your blood from an outside source, such as a blood bank. Platelet transfusions do carry the risk of complications, including allergic reactions that may range from mild to life threatening. In general, it is better to prevent a low platelet count than to treat it once it occurs.

This content was last modified on November 20, 2007 .
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health